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1. Which
aaata
(b)
(c)
(d)
a ratio.
a nuII hlpothesis.
a variable.
the value of a variable.
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of the following is not an airn of research planning?
(a) To select an appropriate research strategy.
(b) To ignore previous research evidence.
(c) To formulate appropriate aims.
(d) To select relevant variables for study.
2. Thirty-five (35) degree Centigrade is an example of........
3. !{hich of the following is unique to experimental research
strategy?
(a) Participant observations.
(b) Selection of cases to be studied.
(c) Assignnent.
(d) Definition of PoPulation.
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4. Which of the following is common to both experimental and
non-experimental research stratery?
. . . . . (a) Experinental hypothesis.
. o... (b) Selection of caseg to be studied.
(c) Field research.
(d) Assignment.
5. As sarnple size increases..........
..... (a) the sanple becomes more biased.
..... (b) the ecological validity of the investigation
increases.
..,.. (c) the population becomes more accesible.
(d) the sampling error decreases.
6, A representative sanple ........
(a) consists of at least 500 cases.
..... (b) must be a random sample.
(c) is defined as the inverse of the square root ofthe sanple size.
. .. . . (d) reflects preciseJ-y the crucial dimensions of apopulation.
341
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7. If a study is externally valid then.
(a) its results can be generalized to other equivalent
settings.
(b) it rnust have been an experiment.
(c) quota sanpling must have been used-
(d) aII the subjects in the sample must have been
equivalent.
Which of the following experlmental desiEn could control all
the threats to internal validitY?8.
(a)
..... (b)
..... (c)
(d)
The Pre-Test, Post-Test Control Group Design.
The Static Group Comparison Design.
The One Group, Pre-Test, Post Test Design.
The one-Short Case StudY.
Questl.on 9 12 rof,sr to the tollorLng caac.
A study to determine the analgesic effect of a new drug (XYZ) was
conducled among sanple of 5O patients in a nedical unit. Measurement
of pain thresf,old -(PT) is blsed on pain reported by_ p-atiells
aft6r pinprick to ttre iignt arm. 25 patients were warded on thefirst troor and given Zoonrg oral dose of xyz and the PT stag
measured 4 hours -later. The other 25 patients were warded on the
second floor and was given placebo oral tablet and the PT was
measured 4 hours later.- A significantly lower PT was found in the
XVZ group compared to the placebo group which the researcher
attribute to XYZ analgesic effect.
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9. The dependent variable in this study is,.
... . . (a) the PT
. o . .. (b) drug XYZ
..... (c) the nethod of assignment
,.. o o (d) the tlpe of treatment.
10. The independent variable in this study is...
(a) the PT
....o (b) drug XYZ
..... (c) the method of assignment
.. . .. (d) the tlpe of treatment.
11. The main threat to internal val-idity in this researcttis.......
.,... (a) nortality.
..... (b) history.
.. o.. (c) maturation.
.. t.. (d) regression to the mean.
( FcP ss6 )
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L2. I{hat type of experinental design has been employed by the
researcher?
. o... (a) The Solomon Four-Group Design.
.. o.. (b) The Pre-Test, post-Test Control Group Design.
o o... (c) The Static Group Design.
...., (d) The One-Group, Pre-Test, post-Test Design.
13. t{hich of the forlowing tests is appropriate for anaryzingdata where 3 or more groups lrere used ?
..... (a) t-teEt
..... (b) z-test
(c) Sign test
(d) Chi-square test
14. Which of the following statenent is true ?
..,.. (a) ANOVA is a non-parametric test,
..... (b) Chi-aquare teEt should be used for nominal data.
..... .(c) The choice of a statistical test is not dependent
on the study design.
. e... (d) Z-test is appropriate for data on a ratio scale.
15. Which of the following statements is true ?
(a) Cmax after an IV bolus doEe is affected by thehalf-life of the drug.
..... (b) Amount of drug in the body after an fV injectionis linearly related to plasma concentration.
r.... (c) The unit of clearance is HOUR.
..... (d) The half-life of a drug usually changes with dose.
...7 l-
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15. Which of the following factors can decrease theophylline
clearance ?
(a) t{arijuana
(b) Children of aged 1 9 Years.
..... (c) Phenytoln therapy
(d) Cor pulutonale
L7. Which of the following conditions is not an indication for
theophyltine serum level monitoring ?
(a) Asthnratic with cardiac decompensation, liver
cirrhosis, and respiratory insufficiency'
(b) Patients developed tachycardia on IV arninophylline
infusion.
..... (c) chronic aEthuratic with variable regponse despitedaily theophylllne dose of 25 mq/kg"
(d) Chronic bronchitic on beta-agonist, 
-anticho-Iinergics and theophylline developed fine tremors.
18. Which of the followinq drugs rnay significantly increase
theophylline serum concentrations ?
(a) Isoniazid
(b) Phenobarbital
(c) Oral contraceptive
{d) Rifanpicin
345
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19. Wtrich of the following conbinations is true ?
(a) Pneumonia - increased theophylline concentratlon
(b) InfLuenza - decreased theophylline concentration
(c) Hyperthyroidisu - increased theophylline
concentration.
(d) Heart failure - decreased theophylline
concentration
2a. Which of the folLowing is the rationale for early
conversion from intravenous to oral theophylline therapy ?
(a) OraI theophyllj.ne therapy is less expensive thanIV therapy.
.. o.. (b) Oral theophylline therapy is as effective and
cause no more adverse effects than IV therapy.
..... (c) Continuous IV theophylline infuEion does not
always infuse as ordered (e.9. punp failure' nurse
error) .
..... (d) AIl of the above
2L. Which of the following statenent is not true ?.
..... (a) Rapid IV adrninistration of, theophylline is usually
associated with hypotension, vascular collapse and
flushing.
(b) BradycardLa is the moet common sign associated
with theophylline toxicitY.
..... (c) The occurence of seizures may not be correlated totheophylline serum levels.
(d) The incidence of theophylline toxicity is variable
due to different parameters used in most studies.
.9 l-
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22. lfhich of following nay not be contributed to the failure of
theophylline therapy ?
..... (a) Possibility of irreversible component of the
airways diseage.
.. o.. (b) Possibility of theophylline overdoses.
..... (c) Possibility of unresolved concurrent pulmonaryinfection.
(d) Possibility of ethylenedianine hypersensitivity.
23. l{hich of the following LElare neasure(s) of disease
occurrence?
. o... (a) Incident rate
(b) Cunmulative incidence
..... (c) Prevalence
. o... (d) AII of the above
24. Which of the following can be clagsified under observational
study design ?
..... (a) Case reports
. o... (b) case Eerlee
(c) Incidence studies
..... (d) A11 of the above
347
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25, l{hich of the following is the strongest study design forinferring cauEal relationship ?
26. A study that starts with the identification of persons
with the disease of interest and a euitable control group
of persons without the disease to establlsh a causal
aesociation between a dieease and an exposure is known as
a to....
27.
(a) Cohort study
(b) Case-control study
(c) CrosE-sectional study
(d) Randonised clinical trial
(a) cohort study
(b) case-control
(c) randonised trial
(d) cross-sectional study
(a) retrospective study
(b) prevalence study
(c) prospective study
(d) disease frequency survey
A case-control study is also known as a....,
p{8
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Zg. A study that obEerves a population for a sufficient number
of per-son-yearE to generitl reflable incidence or nortality
ratbs in the population subsets is knorf,n as a ...
..... (a) cohort studY
..... (b) case-control
..... (c) randomised trial
..... (d) cross-sectional etudY
29. I{hich of the following are advantageE of a case-control
study ?
(i) 'It is well suited to the study of rare diseaseE
( ii) It is relatively inercpensive
(iii) It requires relatively few subjects
(iv) It allows study of rnultiple potential causes
of a disease
(a) (i) and (iii) onIY
(b) (ii) and (iv) onIY
..... (c) (i), (ii) and (iil) onIY
(d) (i), (ii) 
' 
(iii) & (iv)
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30. Which of the followins are linitations of a case-control
study ?
(i) It reties on recall or recorrls for information
of past exposureE
(ii) Validation of infornration is difficuLt or sometimes
impossible
(iii) Selection of an appropriate comparison may bedifficult.
(iv) Rates of diEease in exposed and unexposedindividuals cannot be determined
.. o o, (a) (i) and (iii) only
... o. (b) (ii) and (iv) onIY
o.... (c) (i), (ii) and (iii) onIY
..... (d) (i), (ii), (iii) & (iv)....
31. Which of the following are advantages of a cohort study
design?
(i) ft is well" suited to the study of rare diseases
(ii) It allows for calculation of rates of disease in
exposed and unexposed individuals
(iit) It requires relatively few subject,s
(iv) It allows study of multiple potential effects of agiven exposure
3'50
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..... (a) (i) and (iii) onlY
.. ... (b) (if ) and (iv) onIY
..... (c) (i), (ii) and (iii) onlY
..... (d) (i), (ii), (iii) & (iv)
32. Which of the following are limitations of a cohort study
design ?
(i) It requires large numbers of subjects to study
rare diseases
(ii) RelativeJ.y expensive to conduct
(iii) Maintaining follow-up is difficult
(iv) Validation of information is difficult or
inpossibLe
o.... (a) (i) and (iii) onlY
..,,. (b) (ii) and (iv) onlY
o.,.. (c) (i) 
' 
(ii) and (iii) onlY
.... J (d) (i) 
' 
(ii) 
' 
(iii) & (iv)
33. AIl of the following are observational study design usedin epidemiological research except....
..... (a) cohort studY
..,.. (b) case-control
...., (c) randomised trial
(d) cross-sectional studY
...L41-
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34. Feature(s) of a good clinical trial includes
..... (a) randomized
, .... (b) blinded
(c) prospective
.... o (d) All of the above
35. A drug exposure and disease status or symptoms aredeternined at the same point in tine. ThiE lcind of studyis called....
..... (a) a cohort study
..... (b) a clinical trial
..... (c) a case-control study .
..... (d) a cross-sectional study
36. Randomization iE the most eseential feature of ...... r
.. o.. (a) a case-control study
... o. (b) a cohort study
..... (c) a cross-sectional study
.... o (d) none of the above
352,
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37. Prevalence of a disease in a population can be estimated
from ...
..... (a) a case-control study
o.... (b) a cohort study
..... (c) a cross-sectional study
..... (d) a randomised clinical trial
38. which of the following observational study design is
not analytical in their approach ?
. o... (a) a cohort study
..... (b) a case-control study
..... (c) a cross-sectional study
.... o (d) a population-based mortality studies
39. Which of the following observational study design isdescriptive in their approach ?
,.... (a) A case report
..,.. (b) A case series
..,.. (c) An incidence Etudies
..,.. (d) A1I of the above
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40. Which of the following is true about low frequency effects ?
(a) ft can only be detected in large popuJ.ations
(b) It manifest after long period of use
(c) It manifest after long latency period
(d) None of the above
41. If an adverse effect is suspected to occur in one out of
5OTOOO subjects, how many subjects need to be observed in
order to be 95t likely to detect it ?
..... (a) lOOrOO0
...., (b) l5orOoo
..... (c) 20Or000
....o (d) 25Or00o
42. Which of the following is not a rnodifier of efficacy ?
..... (a) Concurrent drugs
..... (b) Disease severitY
..... (c) Lifestyle
..... (d) None of the above
43. A valid study means that....
(a) the results are consistent
(b) the results are reProducible
..... (c) it accurately measures the outcome of interest
(d) all of the above aPPlies
354
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44. A reliable study means that...
(a) the results are consistent
. o... (b) the reEults are reproducible
. . .. . (c) both (a) and (b) aPPlies
..... (d) none of the above aPPIies
45. Which anticonvulEant drug requiree therapeutic monitoring
of phenobarbital serum levels as well as its own ?
(a) Phenytoin
(b) Prinidone
o . . . . (c) Carbamazepine
.. ... (d) Ethosuxiruide
46. Auto-induction is a unique characteristic of
(a) phenytoin
(b) primidone
r . . . . (c) carbanazepine
.... o (d) ethosuxinide
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47. Which of the following is
effect of aminoglycosides
regrardi.ng post antibiotic
(a) It is the toxic effect asEociated with the highpost aminoglycosLde concentrations.
(b) It correlates with the extent of peak
concentration above the ninimum inhibitory
concentration.
..... (c) It is the toxis effect associated with highpre-aminoglycoside concentration .
It can be prevented by giving single daily doses...... (d)
48. Which of the following contributes to the variability inphenytoin plasna concentrations ?
(i) Nonlinear kinetics
( ii ) Bioavail.abilitY
(iii) Drug interactions
(iv) Non compliance
(a) (i) only
(b) (i) and (ii) only
(c) (i), (ii) and (iii) onIY
(d) (i), (ii), (iii) and (iv).
true
?
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49. l{hich of the following is/are true regarding drug
metabolisut ?
(i) Adninistration of phenobarbitone to a pre911nt
#**i;;-;;;"1; il increased 
drus metaborism
(ii)Antipyrineisnotusefu}asamodeltoestimate
hydrbxYfation kinetics of drugs'
(iii) Rifanpicin is a netabolic inducer'
( iv) I;:;*$li:.L::"1..- w*h phenvtoin kinetics ar
(a) (i) onlY
. o... (b) (i) and (ii) onlY
..... (c) (i), (ii) and (iii) onlY
o.... (d) (i), (ii), (iii) and (iv)'
50.Whichofthefollowingis/areconsideredforthe
selection of an aPpropiiat! statistical test?
(i) The scale of measurement'
(ii) Measurements from independent subjects or
rePeated in the same subject'
(iii) The number of groups studied'
(iv) SanrPIe size.
. . . . . (a) (i) and (ij-i) onIY'
(b) (ii) and (iv) onIY'
(c) (i), (ii) dan (iii) onlY'
(d) (iv) onIY.
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ScctLon g
1. Mr. D.8., is a 76 year o1d man who has been on amino-phylLine conEtant IV infuEion at a rate of 25rmglhr for 15hours. A theophylLine concentration determined at this tine(15 hours after the start of the infusion) is L6.2 ncg/nl.
Baseline data:
Weight: 45 kg
Medical history: Congestive heart failure for 10 yearsPepticulcerx5yearsSocial history: Smokes 2 packs per dayConcurrent nedications :
Digoxin 0.125m9 ODCinetidine 800m9 q hsSalbutamol inhaler ii puffs QIDBecotide inhaler ii puffs QID
A. Is the measured theophylLine concentration at eteady-
state ?
Give your reasons and state any aseumption(s) you make.
( 10 marks )
B. Decide if the adrninistration rate should be changed.
Give reasons for your decision.
( 15 marks )
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A. Write short notes on the following :
(1) State the dlfferenceE between statistical and
clinlcal significance of a statistical test.
( 5 marks )
(ii) Explain the meaning of a statistical power in a study
( 5 narks )
(iii) State the criteria for the selection of a
statistical test.
( 2 marks )
B. (i) Explain the najor differences between a case-
control and a cohort study. Provide example(s)to illustrate these differences'.
( 9 marks )
(ii) List the advantages and disadvantages of each of
these methods.
( 4 narks )
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Normal Lahoratory Values
L . Ammon j-a I O-LLO ncg/dl or 47 -65 unol/L
2. Arnilase 4-25 lulnl
3. BillirubinDirect 0-0.2 mg/gl O-3 unol/LIndirect 0.2-0.8 urq/d1 30-14 unol/LTotal 0.2-L ng/CI 30-17 umol/L
4. COZ 20-30 mEq/L 24-30 nMol/L
5. pCOz 35-45 mmHq
6. cr 100-106 nEq/L 100-105 nMol/L
7. cpk 50-170 U/L
8. Creatinine (SCr) 0.6-L.5 nrg/dl 60-130 umol/L
9. Random blood sugar 70-L10 rng/dl 3-l-O unol/L
10. Iron 50-L5o mcg/dI 9.0-26.9 umolll,
11. Lactic 7A-2Io TU/L
dehydrogenase
L2. Magnessium L.5-2.o rnEq/L 0.8-L.3 nMol/L
13. pOZ 75-100 mnHg
L4. pH 7 ,35-7 .45
15. , Acid phosphataseMale 0.13-0. 53 rU/rn1 36-L76 nmol s-1/LFemale 0. L0L-0. 65 lU/ri,l 2 . 8-156 nmol s't /L
L6. Alkaline 39'L3-7 TU lLphosphatase
t7 . Phosphorous 3 . 0-4 .5 rn9/d1 L. 0-1. 5 mMol/L
18. Potassium (K+) 3.5-5.0 mEq/L 3.5-5.0 mMol/L
L9. Calcium (caz+) B.s-10.5 mg/dl 2'1'-2.6 nMol/L
20. Sodium (Na+) 135-145 nrEg/L 135-145 mMol/L
21. Bicarbonate (HCo?-) 24-38 nEq/L 24-28 nMol/L
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22. Protein
TotaI
Albunin
Globuli-n
Transferrin
23. Transaminase
24.
25.
26.
P
L
u
B
E
Platelate (PIt)
27. ESR Male
FemaIe
28. Hematocrit
Male
FemaIe
29. Hernoglobine (Hgb)
Male
FemaIe
30., Prothronbin tirne
31.
32.
(PT)
APTT
Creatinine
Clearance(crcl)
33. TT+
34. RT3U
35. FTI
6.0-8 ,5 c1ldJ-
3 .5-5.0 9/d12,3-3.5 g/dl
2OO-400 ng/dl
0-40 Iv/L
B-25 mg/dl
3-7 ng/dI
5O-8s glL
35-50 g/L
23-35 glL
2.0-e.0 glL
o-0.32 umol 
"'L/n
2.9-8.9 mMol/L
0.18-0.42 nMol/L
(scor)
BUN
Uric Acid
Blood Pictures
Red blood ce1l (RBc)Male 4.8'6.4
Female 4.2-5.4
White blood ce1I(WBC) 4.
x 1o:/nn:
x loo/mmr
o-ri . o' x to3 /rnm3
60-7 5*
20-4Az
4-82
0-L?
1-38
2oo-4oo x to37rnn3
0-10 mm/jan (Wintrobe)
0-15 nnljan (Wintrobe)
45-522
37 -Aez
1"3-18 g/dL
t2-L6 g/dI
75-1008 nilai asas
25-37 saat
105-150 rnl/rnin/ 1.73 m2
3.O-7.5 mcg/dl
25-35t
L.3-4.2
-ooOoo-
362
3NoRMALHEMoDYNAMICVALUESANDDERIVEDINDICES
Norrnal Value Units
PAPs/D/MPulrnonaryArtery^Pressure25/L2/:.6nnHgr
SYsto t ic / D ia stol icl l'Iean
PCWP Pulmonary capillary Wedge 5'12 mm Hg
BP S/D/YL Blood Pressure
SYsto li-c/ Diastol iclMean
CO Cardiac OutPut
RAP Right Atrial Pressure(Mean)
Pressure (rnean)
Cardiac Index
sv
SVI
PVR
TPVR
Lzol80/93 mm Hg
4-6 Liters/min'
2'6 rnrn Hg
CI
co
TPVR Total PeriPheral VascularResistance}iBP . RAP
' 2,5-3 . 5 Liters/m Ln/mz
900-L4oo dYnes.sec'cm-e
xB0
co
UI
BodY Surface Area
Stroke Volume 60 80 mI/beat
SV=
Heat Rate
stroke Vo1ume Index 30 50 rnl/beat/n2
SVI
SVI=
BodY Surface Area
Pu1monarY Vascular
Resistance
MPAP - PCWP
PVR: x80
co
LVSWI Left Ventricular Stroke
work rndex 
Lar DLrvr\r= 35-80 gm-m7m2/beat
LVSWr = (MBP-PCWP) (sVI) (' 0136)
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